THERAVANCE BIOPHARMA INC
NASDAQ: TBPH (Theravance Biopharma, Inc.)
Last update: 1 hour ago17.01
-0.01 (-0.06%)
| Previous Close | 17.02 |
| Volume | 420,492 |
| Price / Earnings (Forward) | 9.73 |
| Price / Sales | 8.47 |
| Price / Book | 3.05 |
| 52 Weeks Range |
| Profit Margin | -89.38% |
| Operating Margin (TTM) | -93.80% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Total Debt/Equity (MRQ) | 29.01% |
| Current Ratio (MRQ) | 4.77 |
| Operating Cash Flow (TTM) | 32.53 M |
| Levered Free Cash Flow (TTM) | 4.64 M |
| Return on Assets (TTM) | -7.98% |
| Return on Equity (TTM) | -31.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Theravance Biopharma, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.48% |
| % Held by Institutions | 91.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Jun 2026 | 9,212,252 |
| Weiss Asset Management Lp | 30 Jun 2026 | 7,457,060 |
| Newtyn Management, Llc | 30 Jun 2026 | 3,434,191 |
| Irenic Capital Management Lp | 30 Jun 2026 | 2,760,948 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |